<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002960</url>
  </required_header>
  <id_info>
    <org_study_id>C95084</org_study_id>
    <secondary_id>SPRI-I/C95-084</secondary_id>
    <secondary_id>NCI-V97-1181</secondary_id>
    <nct_id>NCT00002960</nct_id>
  </id_info>
  <brief_title>SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)</brief_title>
  <official_title>A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit&#xD;
      tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of SCH-58500 in treating patients who have&#xD;
      recurrent or persistent primary ovarian, fallopian tube, or peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the safety of SCH-58500 (recombinant adenoviral vector containing p53&#xD;
      tumor suppressor gene) when given as a single or multiple intraperitoneal instillation in&#xD;
      combination with chemotherapy to patients with peritoneal carcinomatosis demonstrating p53&#xD;
      mutant ovarian, fallopian tube, or peritoneal carcinoma. II. Assess the biological activity&#xD;
      of SCH-58500 by confirming wild type p53 gene expression. III. Assess the stability of&#xD;
      SCH-58500 infection and expression by collection and analysis of serial, posttreatment,&#xD;
      ascites specimens in a subset of 5 patients. IV. Assess the pharmacokinetics of SCH-58500 by&#xD;
      serum and peritoneal fluid measurements. V. Document any clinical evidence of antitumor&#xD;
      activity in these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an abbreviated dose escalation, multicenter study of SCH-58500. Patients&#xD;
      receive SCH-58500 by intraperitoneal instillation on days 1-5 (depending on dose level).&#xD;
      Patients undergo ascites fluid and tumor sampling before and after intraperitoneal&#xD;
      instillation. The ascitic fluid or tumor and normal tissue are then submitted for cytologic&#xD;
      or histopathologic examination and biological activity analysis. Cohorts of 3-6 patients&#xD;
      receive escalating doses of SCH-58500 until 3 patients experience dose limiting toxicity or&#xD;
      until the highest planned dose is reached. Patients are followed at 2 months, every 3 months&#xD;
      for 1 year, and then yearly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">59</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant adenovirus-p53 SCH-58500</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian&#xD;
        tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis&#xD;
        from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have&#xD;
        ascites and tumor accessible by laparoscopic or percutaneous biopsy Immunohistochemical&#xD;
        evidence of p53 gene mutation in the ascitic fluid cell block or primary tumor biopsy or&#xD;
        other documented mutation&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Life expectancy: At least 3 months Performance&#xD;
        status: Karnofsky 60-100% Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count&#xD;
        at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 1.5&#xD;
        mg/dL AST/ALT less than 1.5 times the upper limit of normal (ULN) Alkaline phosphatase less&#xD;
        than 1.5 times ULN Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater&#xD;
        than 50 mL/min Other: Ability to tolerate paired paracenteses or biopsies (percutaneous or&#xD;
        laparoscopic) HIV negative No adenoviral infections determined by ELISA screening No&#xD;
        uncontrolled serious bacterial, viral, fungal or parasitic infection No known or suspected&#xD;
        hypersensitivity to study drug or any excipient used in formulation or delivery system No&#xD;
        underlying medical condition that would obscure interpretation of adverse events Not&#xD;
        pregnant or nursing Fertile patients must use effective contraception for at least 1 month&#xD;
        before, during, and 6 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 1 month since prior biologic therapy&#xD;
        and recovered Chemotherapy: At least 3 months since local intraperitoneal antitumor therapy&#xD;
        directed against peritoneal carcinomatosis and recovered At least 1 month since systemic&#xD;
        chemotherapy for ovarian, fallopian tube, or peritoneal cancer or an unapproved indication&#xD;
        and recovered Endocrine therapy: At least 3 months since any systemic corticosteroid&#xD;
        therapy Radiotherapy: At least 1 year since prior total abdominal radiotherapy Surgery: Not&#xD;
        specified Other: At least 3 months since prior investigational therapy and recovered At&#xD;
        least 3 months since prior immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Ann Horowitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Schering-Plough</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 2002 Jul;9(7):567-72. doi: 10.1038/sj.cgt.7700473.</citation>
    <PMID>12082456</PMID>
  </results_reference>
  <results_reference>
    <citation>Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul;9(7):553-66. doi: 10.1038/sj.cgt.7700472.</citation>
    <PMID>12082455</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2004</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>malignant ascites</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

